Histological specificity of alterations and expression of KIT and KITLG in non-small cell lung carcinoma

Genes Chromosomes and Cancer

Volumn 52, Issue 11, 2013, Pages 1088-1096

  Salomonsson, Annette ^a   Jönsson, Mats ^a   Isaksson, Sofi ^a   Karlsson, Anna ^a   Jönsson, Per ^a   Gaber, Alexander ^a   Bendahl, Pär Ola ^a   Johansson, Leif ^a   Brunnström, Hans ^a   Jirström, Karin ^a   Borg, Åke ^a   Staaf, Johan ^a   Planck, Maria ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; LIGAND; MESSENGER RNA; PROTEIN TYROSINE KINASE INHIBITOR; RNA 18S; TYROSINE KINASE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DRUG TARGETING; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOKING; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; VALIDATION STUDY;

EID: 84884704288     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22103     Document Type: Article

References (46)

1. Araki K, Ishii G, Yokose T, Nagai K, Funai K, Kodama K, Nishiwaki Y, Ochiai A. 2003. Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. Lung Cancer 40:173-180.
2. Arber DA, Tamayo R, Weiss LM. 1998. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol 29:498-504.
3. Beasley MB, Brambilla E, Travis WD. 2005. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 40:90-97.
4. Bellone G, Silvestri S, Artusio E, Tibaudi D, Turletti A, Geuna M, Giachino C, Valente G, Emanuelli G, Rodeck U. 1997. Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1. J Cell Physiol 172:1-11.
5. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Jr., Marks JR, Dressman HK, West M, Nevins JR. 2006. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353-357.
6. Blumenschein GR, Jr., Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M. 2009. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 27:4274-4280.
7. Bryant CM, Albertus DL, Kim S, Chen G, Brambilla C, Guedj M, Arima C, Travis WD, Yatabe Y, Takahashi T, Brambilla E, Beer DG. 2010. Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: An international validation study. PLoS One 5:e11712.
8. Butnor KJ, Burchette JL, Sporn TA, Hammar SP, Roggli VL. 2004. The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: A study of 96 cases using a single-source antibody with a review of the literature. Arch Pathol Lab Med 128:538-543.
9. Casali C, Stefani A, Rossi G, Migaldi M, Bettelli S, Parise A, Morandi U. 2004. The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg 77:247-252; discussion 252-243.
10. Ezzati M, Henley SJ, Lopez AD, Thun MJ. 2005. Role of smoking in global and regional cancer epidemiology: Current patterns and data needs. Int J Cancer 116:963-971.
11. Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, Bhattacharjee A, Socinski MA, Perou C, Meyerson M. 2006. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 24:5079-5090.
12. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. 1998. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580.
13. Holtkamp N, Ziegenhagen N, Malzer E, Hartmann C, Giese A, von Deimling A. 2007. Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. Neuro Oncol 9:291-297. http://www.ncbi.nlm.nih.gov/geo/.
14. Iyoda A, Travis WD, Sarkaria IS, Jiang SX, Amano H, Sato Y, Saegusa M, Rusch VW, Satoh Y. 2011. Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma. Exp Ther Med 2:1041-1045.
15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin 61:69-90.
16. Jonsson G, Staaf J, Olsson E, Heidenblad M, Vallon-Christersson J, Osoegawa K, de Jong P, Oredsson S, Ringner M, Hoglund M, Borg A. 2007. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 46:543-558.
17. Kim WK, Park M, Kim YK, Tae YK, Yang HK, Lee JM, Kim H. 2011. MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation. Clin Cancer Res 17:7584-7594.
18. Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, Kris MG, Pizzo B, Tyson L, Dunne M, Heelan RT. 2005. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: A phase II clinical trial. Cancer 103:2128-2131.
19. Krystal GW, Hines SJ, Organ CP. 1996. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 56:370-376.
20. Krystal GW, Honsawek S, Litz J, Buchdunger E. 2000. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6:3319-3326.
21. Lennartsson J, Ronnstrand L. 2006. The stem cell factor receptor/c-Kit as a drug target in cancer. Curr Cancer Drug Targets 6:65-75.
22. Lopez-Martin A, Ballestin C, Garcia-Carbonero R, Castano A, Lopez-Rios F, Lopez-Encuentra A, Sanchez-Cespedes M, Castellano D, Bartolome A, Cortes-Funes H, Paz-Ares L. 2007. Prognostic value of KIT expression in small cell lung cancer. Lung Cancer 56:405-413.
23. Micke P, Basrai M, Faldum A, Bittinger F, Ronnstrand L, Blaukat A, Beeh KM, Oesch F, Fischer B, Buhl R, Hengstler JG. 2003. Characterization of c-kit expression in small cell lung cancer: Prognostic and therapeutic implications. Clin Cancer Res 9:188-194.
24. Micke P, Hengstler JG, Albrecht H, Faldum A, Bittinger F, Becker K, Wiewrodt R, Fischer B, Buhl R. 2004. c-kit expression in adenocarcinomas of the lung. Tumour Biol 25:235-242.
25. Moreira AL, Gonen M, Rekhtman N, Downey RJ. 2010. Progenitor stem cell marker expression by pulmonary carcinomas. Mod Pathol 23:889-895.
26. O'Brien KM, Orlow I, Antonescu CR, Ballman K, McCall L, Dematteo R, Engel LS. 2013. Gastrointestinal stromal tumors, somatic mutations and candidate genetic risk variants. PLoS One 8:e62119.
27. Pelosi G, Barisella M, Pasini F, Leon ME, Veronesi G, Spaggiari L, Fraggetta F, Iannucci A, Masullo M, Sonzogni A, Maffini F, Viale G. 2004a. CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: Relevance to prognosis in a subset of adenocarcinoma patients. Mod Pathol 17:711-721.
28. Pelosi G, Masullo M, Leon ME, Veronesi G, Spaggiari L, Pasini F, Sonzogni A, Iannucci A, Bresaola E, Viale G. 2004b. CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: A comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas. Virchows Arch 445:449-455.
29. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45.
30. Pietsch T, Nicotra MR, Fraioli R, Wolf HK, Mottolese M, Natali PG. 1998. Expression of the c-Kit receptor and its ligand SCF in non-small-cell lung carcinomas. Int J Cancer 75:171-175.
31. Ramos AH, Dutt A, Mermel C, Perner S, Cho J, Lafargue CJ, Johnson LA, Stiedl AC, Tanaka KE, Bass AJ, Barretina J, Weir BA, Beroukhim R, Thomas RK, Minna JD, Chirieac LR, Lindeman NI, Giordano T, Beer DG, Wagner P, Wistuba, II, Rubin MA, Meyerson M. 2009. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther 8:2042-2050.
32. Rossi G, Cavazza A, Marchioni A, Migaldi M, Bavieri M, Facciolongo N, Petruzzelli S, Longo L, Tamberi S, Crino L. 2003. Kit expression in small cell carcinomas of the lung: effects of chemotherapy. Mod Pathol 16:1041-1047.
33. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrao Miziara JE, Balint B, De Marinis F, Keller A, Aren O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N. 2010. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28:1835-1842.
34. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK, Lively T, Jacobson JW, Beer DG. 2008. Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med 14:822-827.
35. Siegel R, Naishadham D, Jemal A. 2012. Cancer statistics, 2012. CA Cancer J Clin 62:10-29.
36. Sihto H, Sarlomo-Rikala M, Tynninen O, Tanner M, Andersson LC, Franssila K, Nupponen NN, Joensuu H. 2005. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 23:49-57.
37. Soria JC, Johnson BE, Chevalier TL. 2003. Imatinib in small cell lung cancer. Lung Cancer 41 Suppl 1:S49-53.
38. Spira A, Beane J, Shah V, Liu G, Schembri F, Yang X, Palma J, Brody JS. 2004. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci U S A 101:10143-10148.
39. Staaf J, Isaksson S, Karlsson A, Jönsson M, Johansson L, Jönsson P, Botling J, Micke P, Baldetorp B, Planck M. 2013. Landscape of somatic allelic imbalances and copy number alterations in human lung carcinoma. Int J Cancer 132:2020-2031.
40. Staaf J, Jonsson G, Jonsson M, Karlsson A, Isaksson S, Salomonsson A, Pettersson HM, Soller M, Ewers SB, Johansson L, Jonsson P, Planck M. 2012. Relation between smoking history and gene expression profiles in lung adenocarcinomas. BMC Med Genomics 5:22.
41. Staaf J, Jonsson G, Ringner M, Vallon-Christersson J. 2007. Normalization of array-CGH data: influence of copy number imbalances. BMC Genomics 8:382.
42. Staaf J, Jonsson G, Ringner M, Vallon-Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson BA, Malmstrom PO, Johannsson OT, Loman N, Barkardottir RB, Borg A. 2010. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 12:R25.
43. Sun S, Schiller JH, Gazdar AF. 2007. Lung cancer in never smokers--a different disease. Nat Rev Cancer 7:778-790.
44. Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R. 2000. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 19:3521-3528.
45. Venkatraman ES, Olshen AB. 2007. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23:657-663.
46. Vlahovic G, Crawford J. 2003. Activation of tyrosine kinases in cancer. Oncologist 8:531-538.